FindTrial
Sign In

"A study to compare two drugs Seratconazole versus Luliconacole for improvement of symptoms and to compare the side effects"

"A comparative study to evaluate the efficacy and safety of topical Sertaconazole versus Luliconazole in the patient of mild tinea corporis at a tertiary care center"

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/10/046157
Enrollment
70
Registered
2022-10-04
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L089- Local infection of the skin and subcutaneous tissue, unspecified Health Condition 2: L088- Other specified local infections of the skin and subcutaneous tissue

Interventions

Intervention1: Topical Sertaconazole 2% cream BD: Duration: 6 weeks. The patient will be instructed to take a sufficient quantity of topical cream to cover/smear the affected area in

Sponsors

Yuvarani R
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients willing to give written informed consent and willing for follow up 2. Patients of either gender, aged 18- 60 years 3. Patients with mild tinea corporis lesions ( confined to limbs and trunk with only KOH mount report positive and treatment-naive.

Exclusion criteria

Exclusion criteria: 1. Patients not willing to give informed consent and not willing for follow up 2. Patients with deep fungal infections 3. Patients with tinea infection on other parts of the body (scalp, groin, feet, nails, hands, and toes ) 4. Cases of dermatophytosis with a secondary bacterial infection 5. Diabetic and immuno-compromised patients 6. Pregnant and lactating mothers 7. Patients with a history of hypersensitivity to azole and allylamine groups 8. Patients on oral antifungal medications

Design outcomes

Primary

MeasureTime frame
Efficacy is assessed based on clinical cure and mycological cure of tinea lesion. A clinical cure is assessed based on symptoms and signs of tinea lesions namely pruritis, erythema, and desquamation/scaling which are graded depending on intensity. Pruritus by visual analogue score, Erythema by clinicianââ?¬â?¢s erythema assessment score, Scaling is assessed by the clinicianââ?¬â?¢s assessment score will be recorded and analyzed at the end of the 4th week and at the end of the 6th week. A mycological cure will be assessed by KOH Mount at the baseline (1st visit) and at the end of the 6th week.Timepoint: 0,4,6 weeks—

Secondary

MeasureTime frame
Safety is assessed by Adverse drug reactions which will be reported in CDSCO form and severity grading will be done.Timepoint: baseline,4th week,6th week—

Countries

India

Contacts

Public ContactYuvarani R

Bangalore Medical College and Research Institute

yuvaraniramamoorthy97@gmail.com6383240700

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026